Fishers, IN, United States of America

James Allen Knobelsdorf


 

Average Co-Inventor Count = 7.5

ph-index = 1

Forward Citations = 6(Granted Patents)


Location History:

  • Noblesville, IN (US) (2004 - 2006)
  • Fishers, IN (US) (2009 - 2010)

Company Filing History:


Years Active: 2004-2010

Loading Chart...
Loading Chart...
8 patents (USPTO):Explore Patents

Title: James Allen Knobelsdorf: Innovator in Pharmaceutical Science

Introduction

James Allen Knobelsdorf is a notable inventor based in Fishers, IN (US). He has made significant contributions to the field of pharmaceutical science, particularly in the development of compounds that enhance glutamate receptors. With a total of 8 patents to his name, Knobelsdorf's work has the potential to impact various therapeutic areas.

Latest Patents

Among his latest patents, Knobelsdorf has developed innovative compounds aimed at potentiating glutamate receptors. One of his inventions provides pharmaceutical compositions and methods for using these compounds, which are crucial in treating conditions related to glutamate receptor activity. Another patent focuses on a substituted hydroxyphenyl ketone compound, which is also aimed at treating migraines. These inventions highlight his commitment to advancing medical science and improving patient outcomes.

Career Highlights

Knobelsdorf is currently associated with Eli Lilly and Company, a leading pharmaceutical firm known for its research and development in innovative therapies. His role at Eli Lilly allows him to collaborate with other experts in the field and contribute to groundbreaking research.

Collaborations

Some of his notable coworkers include Jeffrey Michael Schkeryantz and Thomas Daniel Aicher. Their collaborative efforts in research and development have further enhanced the impact of their work in the pharmaceutical industry.

Conclusion

James Allen Knobelsdorf's contributions to pharmaceutical science through his patents and collaborations demonstrate his dedication to innovation in medicine. His work continues to pave the way for new treatments and therapies that can significantly benefit patients.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…